Cargando…

Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram

BACKGROUND: The diagnostic value of clinical and laboratory features to differentiate between malignant pleural effusion (MPE) and benign pleural effusion (BPE) has not yet been established. OBJECTIVES: The present study aimed to develop and validate the diagnostic accuracy of a scoring system based...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Aihua, Liang, Zhigang, Yuan, Songbo, Wang, Shanshan, Peng, Weidong, Mo, Yijun, Yang, Jing, Liu, Yanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688822/
https://www.ncbi.nlm.nih.gov/pubmed/34950585
http://dx.doi.org/10.3389/fonc.2021.775079
_version_ 1784618427772567552
author Wu, Aihua
Liang, Zhigang
Yuan, Songbo
Wang, Shanshan
Peng, Weidong
Mo, Yijun
Yang, Jing
Liu, Yanqing
author_facet Wu, Aihua
Liang, Zhigang
Yuan, Songbo
Wang, Shanshan
Peng, Weidong
Mo, Yijun
Yang, Jing
Liu, Yanqing
author_sort Wu, Aihua
collection PubMed
description BACKGROUND: The diagnostic value of clinical and laboratory features to differentiate between malignant pleural effusion (MPE) and benign pleural effusion (BPE) has not yet been established. OBJECTIVES: The present study aimed to develop and validate the diagnostic accuracy of a scoring system based on a nomogram to distinguish MPE from BPE. METHODS: A total of 1,239 eligible patients with PE were recruited in this study and randomly divided into a training set and an internal validation set at a ratio of 7:3. Logistic regression analysis was performed in the training set, and a nomogram was developed using selected predictors. The diagnostic accuracy of an innovative scoring system based on the nomogram was established and validated in the training, internal validation, and external validation sets (n = 217). The discriminatory power and the calibration and clinical values of the prediction model were evaluated. RESULTS: Seven variables [effusion carcinoembryonic antigen (CEA), effusion adenosine deaminase (ADA), erythrocyte sedimentation rate (ESR), PE/serum CEA ratio (CEA ratio), effusion carbohydrate antigen 19-9 (CA19-9), effusion cytokeratin 19 fragment (CYFRA 21-1), and serum lactate dehydrogenase (LDH)/effusion ADA ratio (cancer ratio, CR)] were validated and used to develop a nomogram. The prediction model showed both good discrimination and calibration capabilities for all sets. A scoring system was established based on the nomogram scores to distinguish MPE from BPE. The scoring system showed favorable diagnostic performance in the training set [area under the curve (AUC) = 0.955, 95% confidence interval (CI) = 0.942–0.968], the internal validation set (AUC = 0.952, 95% CI = 0.932–0.973), and the external validation set (AUC = 0.973, 95% CI = 0.956–0.990). In addition, the scoring system achieved satisfactory discriminative abilities at separating lung cancer-associated MPE from tuberculous pleurisy effusion (TPE) in the combined training and validation sets. CONCLUSIONS: The present study developed and validated a scoring system based on seven parameters. The scoring system exhibited a reliable diagnostic performance in distinguishing MPE from BPE and might guide clinical decision-making.
format Online
Article
Text
id pubmed-8688822
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86888222021-12-22 Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram Wu, Aihua Liang, Zhigang Yuan, Songbo Wang, Shanshan Peng, Weidong Mo, Yijun Yang, Jing Liu, Yanqing Front Oncol Oncology BACKGROUND: The diagnostic value of clinical and laboratory features to differentiate between malignant pleural effusion (MPE) and benign pleural effusion (BPE) has not yet been established. OBJECTIVES: The present study aimed to develop and validate the diagnostic accuracy of a scoring system based on a nomogram to distinguish MPE from BPE. METHODS: A total of 1,239 eligible patients with PE were recruited in this study and randomly divided into a training set and an internal validation set at a ratio of 7:3. Logistic regression analysis was performed in the training set, and a nomogram was developed using selected predictors. The diagnostic accuracy of an innovative scoring system based on the nomogram was established and validated in the training, internal validation, and external validation sets (n = 217). The discriminatory power and the calibration and clinical values of the prediction model were evaluated. RESULTS: Seven variables [effusion carcinoembryonic antigen (CEA), effusion adenosine deaminase (ADA), erythrocyte sedimentation rate (ESR), PE/serum CEA ratio (CEA ratio), effusion carbohydrate antigen 19-9 (CA19-9), effusion cytokeratin 19 fragment (CYFRA 21-1), and serum lactate dehydrogenase (LDH)/effusion ADA ratio (cancer ratio, CR)] were validated and used to develop a nomogram. The prediction model showed both good discrimination and calibration capabilities for all sets. A scoring system was established based on the nomogram scores to distinguish MPE from BPE. The scoring system showed favorable diagnostic performance in the training set [area under the curve (AUC) = 0.955, 95% confidence interval (CI) = 0.942–0.968], the internal validation set (AUC = 0.952, 95% CI = 0.932–0.973), and the external validation set (AUC = 0.973, 95% CI = 0.956–0.990). In addition, the scoring system achieved satisfactory discriminative abilities at separating lung cancer-associated MPE from tuberculous pleurisy effusion (TPE) in the combined training and validation sets. CONCLUSIONS: The present study developed and validated a scoring system based on seven parameters. The scoring system exhibited a reliable diagnostic performance in distinguishing MPE from BPE and might guide clinical decision-making. Frontiers Media S.A. 2021-12-07 /pmc/articles/PMC8688822/ /pubmed/34950585 http://dx.doi.org/10.3389/fonc.2021.775079 Text en Copyright © 2021 Wu, Liang, Yuan, Wang, Peng, Mo, Yang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Aihua
Liang, Zhigang
Yuan, Songbo
Wang, Shanshan
Peng, Weidong
Mo, Yijun
Yang, Jing
Liu, Yanqing
Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title_full Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title_fullStr Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title_full_unstemmed Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title_short Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram
title_sort development and validation of a scoring system for early diagnosis of malignant pleural effusion based on a nomogram
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688822/
https://www.ncbi.nlm.nih.gov/pubmed/34950585
http://dx.doi.org/10.3389/fonc.2021.775079
work_keys_str_mv AT wuaihua developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT liangzhigang developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT yuansongbo developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT wangshanshan developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT pengweidong developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT moyijun developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT yangjing developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram
AT liuyanqing developmentandvalidationofascoringsystemforearlydiagnosisofmalignantpleuraleffusionbasedonanomogram